Table 1.
Baseline characteristics of included studies
| Author | Year | Country | N | N in survival analysis | Number of patients with OAC (% total) | Only curative surgery in survival analysis? | Specimen type | CRTx? | Neoadjuvant CRTx? | Analysis method | IHC antibody | Dilution | Percent ‘mutated’ | HR estimation method | Multivariable analysis performed and reported in original paper? |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fléjou39 | 1993 | France | 62 | 62 | 62 (100) | Yes | Surgery | NR | NR | IHC | DO7 (Dako) and PAb1801 | NR | 66 | Extrapolated | No |
| Duhaylongsod40 | 1995 | USA | 42 | 40 | 42 (100) | Yes | Surgery | Yes | Yes | IHC | PAb1801 (Oncogene Science) | NR | 79 | Extrapolated | No |
| Sauter48 | 1995 | USA | 24 | 16 | 24 (100) | Yes | Biopsies | Yes | Yes | IHC | PAb1801 (Oncogene Science) | 1 μg/mL (?) | 50 | Extrapolated | No |
| Wu41 | 1998 | USA | 92 | 90 | 92 (100) | Yes | Surgery | Yes | Yes | LOH+IHC | DO7 (Dako) | 100 | 57 | Reported in text | Yes |
| Ribeiro50 | 1998 | USA | 42 | 35 | 31 (74) | Yes | Surgery | Yes | Yes | Sequencing | – | – | 40 | Reported in text, 95% CIs extrapolated | Yes |
| Soontrapornchai49 | 1999 | Australia | 135 | 51 | 135 (100) | No | Biopsies | Yes | Yes | SSCP | – | – | 36 | Reported in text | No |
| Schneider43 | 2000 | Germany | 59 | 49 | 59 (100) | Yes | Biopsies | Yes | No | Sequencing | – | – | 44 | Reported in text | Yes |
| Ireland42 | 2000 | USA | 37 | 22 | 37 (100) | Yes | N/A | No | No | Sequencing | – | – | 49 | Calculated from raw data | No |
| Aloia51 | 2001 | USA | 61 | 61 | 44 (72) | Yes | Surgery | No | No | IHC | #1801 (Biogenex) | 200 | 67 | Reported in text, 95% CIs extrapolated | Yes |
| Gibson52 | 2003 | USA | 54 | 46 | 41 (76) | Yes | Biopsies | Yes | Yes | Sequencing | – | – | 63 | Reported in text | Yes |
| Falkenback44 | 2008 | Sweden | 54 | 54 | 54 (100) | Yes | Surgery | No | No | IHC | DO7 | 300 | 60 | Calculated from raw data | No |
| Madani45 | 2009 | Canada | 142 | 142 | 142 (100) | Yes | Surgery | No | No | Sequencing+IHC | DO7 (Dako) | 50 | 47 | Reported in text | Yes |
| Cavazzola47 | 2009 | Brazil | 46 | 38 | 46 (100) | Yes | Surgery | No | No | IHC | DO7 (PAb1801 Sigma) | 100 | 52 | Reported in text | Yes |
| Lehrbach46 | 2009 | Brazil | 75 | 75 | 75 (100) | Yes | Surgery | No | No | IHC | DO7 (Novocastra) | NR | 60 | Extrapolated | No |
| Fareed53 | 2010 | UK | 245 | 66 | 83 (81) | Yes | Surgery | Yes | Yes | IHC | DO7? (Vector Labs) | 50 | 30 | Extrapolated | No |
| Kandioler54 | 2014 | Austria | 36 | 36 | 20 (56) | No | Biopsies | Yes | Yes | Sequencing | – | – | 50 | Reported in text | Yes |
CRTx, chemoradiotherapy; IHC, immunohistochemistry; LOH, loss of heterozygosity; NR, not reported; OAC, oesophageal adenocarcinoma; SSCP, single-strand confirmation polymorphism.